创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

伊凯凯, 战琦, 王晓光, 康春生. 外泌体在胶质瘤治疗中的研究进展[J]. 药学进展, 2023, 47(11): 829-836. DOI: 10.20053/j.issn1001-5094.2023.11.004
引用本文: 伊凯凯, 战琦, 王晓光, 康春生. 外泌体在胶质瘤治疗中的研究进展[J]. 药学进展, 2023, 47(11): 829-836. DOI: 10.20053/j.issn1001-5094.2023.11.004
YI Kaikai, ZHAN Qi, WANG Xiaoguang, KANG Chunsheng. Research Progress of Exosomes in the Treatment of Glioma[J]. Progress in Pharmaceutical Sciences, 2023, 47(11): 829-836. DOI: 10.20053/j.issn1001-5094.2023.11.004
Citation: YI Kaikai, ZHAN Qi, WANG Xiaoguang, KANG Chunsheng. Research Progress of Exosomes in the Treatment of Glioma[J]. Progress in Pharmaceutical Sciences, 2023, 47(11): 829-836. DOI: 10.20053/j.issn1001-5094.2023.11.004

外泌体在胶质瘤治疗中的研究进展

Research Progress of Exosomes in the Treatment of Glioma

  • 摘要: 胶质瘤是最常见的原发恶性脑肿瘤。传统化疗药物对胶质瘤靶向性差,且血脑屏障穿透性低,因而在胶质瘤治疗中的应用受到限制。外泌体作为新一代的递药载体,具有良好的生物相容性、稳定性和血脑屏障穿透性,近年来被广泛应用于脑部疾病的靶向递药研究,成果斐然。介绍了外泌体的结构和生物学特性,并对外泌体作为药物递送载体的脑靶向递送策略以及外泌体在胶质瘤治疗中的研究进展进行综述。

     

    Abstract: Glioma is the most common type of primary malignant brain tumor.Traditional chemotherapy drugs often lack sufficient targeting for glioma and have low blood-brain barrier penetration, so their application in glioma treatment is limited.Exosomes, as a new generation of drug delivery carriers with good biocompatibility, stability and blood-brain barrier penetration, have been extensively investigated in targeted drug delivery for brain diseases in recent years, yielding remarkable achievements.In this article, the structure and biological characteristics of exosomes have been introduced.In addition, the brain-targeted delivery strategies using exosomes as drug delivery carriers and the research progress of exosomes in the treatment of glioma have been reviewed.

     

/

返回文章
返回